16^th Clinical Trials on Alzheimer's Disease (CTAD) Boston, MA (USA) October 24–27, 2023: Symposia - 21/11/24

Doi : 10.14283/jpad.2022.129

Il testo completo di questo articolo è disponibile in PDF.

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.

Si connetta per beneficiarne

Il testo completo di questo articolo è disponibile in PDF.

Mappa

Clinical Trial Alzheimer's Disease

S1- THE EFFECTS OF RACE AND GENDER ON AMYLOID POSITIVITY

S2- DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE: ADDITIONAL INSIGHTS FROM TRAILBLAZER-ALZ 2. J.R. Sims¹, T. Iwatsubo², S.M. Greenberg^3,4, M. Mintun¹, A. Atri^5,6, J.A. Zimmer¹, C.D. Evans¹, M. Lu¹, Paul Ardayfio¹, J. Sparks¹, C. Battioui¹, A.M. Wessels¹, A. Atkins¹, S. Shcherbinin¹, H. Wang¹, E.S. Monkul Nery¹, E.C. Collins¹, D.A. Brooks¹(1. Eli Lilly and Company - Indianapolis, IN (United States), 2. Graduate School of Medicine, The University of Tokyo - Tokyo (Japan), 3. Harvard Medical School - Boston, MA, (United States), 4. Massachusetts General Hospital - Boston, MA, (United States), 5. Banner Sun Health Research Institute and Banner Alzheimer's Institute - Sun City and Phoenix, AZ, (United States), 6. Brigham and Women's Hospital - Boston, MA, (United States))

S3- CLINICAL AND ATN BIOMARKER FINDINGS ON THE IMPACT OF AMYLOID REMOVAL IN A 10 YEAR PREVENTION TRIAL - THE DIAN-TU-001. R. Bateman¹, E. Mcdade¹, G. Wang¹, N. Bartelemy¹, Y. Li¹, B. Gordon¹, T. Benzinger¹, L. Ibanez¹, S. Salloway², M. Farlow³, D. Clifford¹, J. Llibre-Guerra¹, C. Supnet¹, C. Xiong¹, J. Hassenstab¹, A. Fagan¹, S. Mills¹, A. Aschenbrenner¹, R. Hornbeck¹, A. Santacruz¹, R. Yaari⁴, G. Klein⁵, R. Doody⁵, M. Baudler⁵, A. Atri⁶(1. Washington University School Of Medicine - St. Louis (United States), 2. Butler Hospital and Warren Alpert Medical School of Brown University - Providence (United States), 3. Indiana University School of Medicine - Indianapolis (United States), 4. Eli Lilly and Company - Indianapolis (United States), 5. Hoffmann-La Roche - Basel (Switzerland), 6. Banner Sun Health Research Institute - Sun City (United States) On behalf of the DIAN-TU Study Team))

S4- LECANEMAB FOR EARLY ALZHEIMER'S DISEASE:LONG-TERM OUTCOMES, PREDICTIVE BIOMARKERS AND NOVEL SUBCUTANEOUS ADMINISTRATION. C. Van Dyck¹, K. Johnson², R. Sperling², M. Irizarry³(1. Yale Alzheimer's Disease Research Center - New Haven (United States), 2. Harvard Medical School - Boston (United States), 3. Eisai Inc. - Nutley (United States))

S5- WHAT CAN WE LEARN FROM THE A4 STUDY? ASSOCIATIONS AMONG LONGITUDINAL COGNITIVE, FUNCTIONAL, BIOMARKER AND IMAGING OUTCOMES. R. Sperling¹, M. Donohue², R. Raman², K. Johnson³, R. Yaari⁴, K. Holdridge⁴, M. Case⁴, J. Sims⁴, P. Aisen², on behalf of the A4 Study (1. Brigham and Women's Hospital Harvard Medical School - Boston (United States), 2. Alzheimer Therapeutic Research Institute, University of Southern California - San Diego (United States), 3. Massachusetts General Hospital, Harvard Medical School - Boston (United States), 4. Eli Lilly and Co. - Indianapolis (United States))

S6- IMPLEMENTING BLOOD BIOMARKERS IN CLINICAL PRACTICE AND TRIALS Presentation 1: Defining the minimum acceptable performance of blood-based biomarkers of Alzheimer's disease for clinical use in symptomatic patients, S. Schindler¹, Ana C. Pereira², D. Galasko^3,4, S. Salloway⁴, M. Suárez-Calvet^5,6, Oskar Hansson⁷(1. Washington University School of Medicine, Department of Neurology, St. Louis (United States), 2. Icahn School of Medicine at Mount Sinai, Department of Neurology, New York, (United States), 3. University of California-San Diego, Department of Neurology, San Diego (United States), 4. Alpert Medical School of Brown University, Departments of Neurology and Psychiatry, Providence (United States), 5. Barcelona βeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona (Spain), 6. Hospital del Mar, Neurology Department, Barcelona (Spain), 7. Lund University, Clinical Memory Research Unit, Lund (Sweden))

S7- INTERCEPT-AD PHASE 1 INSIGHTS AND FINDINGS FROM THE INVESTIGATION OF ACU193, A MONOCLONAL ANTIBODY TARGETING SOLUBLE AB OLIGOMERS. M. Trame¹, M. Dodds¹, E. Cline², J. Moore², H. Zhang², R. Dean², J. Jerecic², G. Sethuraman², E. Siemers², T. Feaster², K. Sundell², V. Skljarevski², T. Poppe³, S. Salloway⁴(1. Certara - Boston (United States), 2. Acumen Pharmaceuticals - Charlottesville (United States), 3. Acumen Pharmaceuticals - London (United Kingdom), 4. Alpert Medical School of Brown University, Providence (United States))

Roundtables

ROUNDTABLE 1- NIA-AA REVISED CRITERIA FOR DIAGNOSIS AND STAGING OF ALZHEIMER'S DISEASE. C. Jack¹, R. Sperling^2,3, O. Hansson⁴, H. Snyder⁵, L. Ryan⁶(1. Mayo Clinic - Rochester (United States), 2. Brigham and Women's Hospital - Boston (United States), 3. Massachusetts General Hospital - Boston (United States), 4. Lund University - Lund (Sweden), 5. Alzheimer's Association - Chicago (United States), 6. National Institute on aging/NIH - Bethesda (United States))

ROUNDTABLE 2- FORGING THE PATH FORWARD: CAPITALIZING ON RECENT ALZHEIMER'S MOMENTUM THROUGH STRATEGIC INVESTMENTS IN NOVEL THERAPEUTICS. H. Fillit¹, P. Scheltens², S. Kohlhaas³, J. Behr⁴, J. Lewcock⁵(1. Alzheimer's Drug Discovery Foundation - New York City (United States), 2. EQT Life Sciences - Amsterdam (Netherlands), 3. Alzheimer's Research UK -London (United Kingdom), 4. Dementia Discovery Fund - London (United Kingdom), 5. Denali Therapeutics - South San Francisco (United States))

Oral Communications

OC01- CLINICAL EFFECTS OF LEWY BODY PATHOLOGY IN CLINICALLY UNIMPAIRED AND COGNITIVELY IMPAIRED INDIVIDUALS. O. Hansson¹, S. Palmqvist¹, P. Parchi²(1. Lund University - Lund (Sweden), 2. University of Bologna - Bologna (Italy))

OC02- NOVEL CSF TAU BIOMARKERS CAN BE USED FOR DISEASE STAGING OF SPORADIC ALZHEIMER'S DISEASE. G. Salvadó¹, K. Horie^2,3,4, N.R. Barthélemy^2,3, J.W. Vogel^1,5, A. Pichet Binette¹, C.D. Chen⁶, B.A. Gordon⁶, T.L.S. Benzinger^6,7, D.M. Holtzman^3,7, J.C. Morris^3,7, S. Janelidze¹, R. Ossenkoppele^1,8,9, S.E. Schindler^3,7, R.J. Bateman^2,3,7, O. Hansson^1,10(1. Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University - Lund (Sweden), 2. The Tracy Family SILQ Center, Washington University School of Medicine - St Louis (United States), 3. Department of Neurology, Washington University School of Medicine - St Louis (United States), 4. Eisai Inc. - Nutley (United States), 5. Department of Clinical Science, Malmö, SciLifeLab, Lund University - Lund (Sweden), 6. Department of Radiology, Washington University School of Medicine - St Louis (United States), 7. Charles F. and Joanne Knight Alzheimer Disease Research Center, Washington University School of Medicine - St Louis (United States), 8. Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc - Amsterdam (Netherlands), 9. Amsterdam Neuroscience, Neurodegeneration - Amsterdam (Netherlands), 10. Memory Clinic, Skåne University Hospital - Malmö (Sweden))

OC03- THE ANTI-AMYLOID BETA «BRAIN SHUTTLE» ANTIBODY TRONTINEMAB RAPIDLY REDUCES AMYLOID PLAQUES IN PEOPLE WITH ALZHEIMER'S DISEASE. L. Kulic¹, F. Alcaraz¹, A. Vogt¹, C. Hofmann¹, P. Barrington², M. Marchesi¹, G. Klein¹, R. Croney³, D. Agnew³, J.A. Abrantes¹, S. Ahlers⁴, P. Delmar¹, I. Wiesel¹, H. Svoboda¹(1. Roche - Basel (Switzerland), 2. TranScrip group - Wokingham (United Kingdom), 3. Roche - Welwyn (United Kingdom), 4. Excelya Germany GmbH - Mannheim (Germany))

OC04- RAPID DETECTION OF THE EARLIEST AMYLOID-RELATED CHANGES IN MEMORY CONSOLIDATION: ASSESSMENT OF LEARNING USING DAILY DIGITAL TESTING. K. Papp¹, R. Jutten¹, D. Soberanes¹, E. Weizenbaum¹, S. Hsieh¹, C. Molinare¹, R. Buckley¹, R. Betensky², K. Johnson¹, D. Rentz¹, R. Sperling¹, R. Amariglio¹(1. Harvard Medical School - Boston (United States), 2. New York University - New York (United States))

OC05- CLINICAL OUTCOMES FROM A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF NE3107 IN SUBJECTS WITH MILD TO MODERATE PROBABLE ALZHEIMER'S DISEASE. C. Reading¹, C. Ahlem¹, J. Palumbo¹, N. Osman¹, M. Testa², D. Simonson¹(1. BioVie Inc. - Carson City (United States), 2. Department of Biostatistics, Harvard T.H. Chan School of Public Health - Boston (United States), 3. Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women's Hospital, Harvard Medical School - Boston (United States))

OC06- PLASMA P-TAU217 FACILITATES A TWO-PHASE SCREENING APPROACH FOR PARTICIPANT SELECTION INTO ANTI-AMYLOID TRIALS. N. Mattsson-Carlgren¹, L. Collij^1,2, A. Pichet Binette¹, R. Ossenkoppele^1,2, R. Smith¹, O. Strandberg¹, S. Palmqvist¹, E. Stomrud¹, N. Ashton³, K. Blennow³, S. Janelidze¹, O. Hansson¹(1. Lund University - Lund (Sweden), 2. Amsterdam UMC - Amsterdam (Netherlands), 3. University of Gothenburg - Gothenburg (Sweden))

OC07- USE OF A BLOOD BIOMARKER TEST IMPROVES ECONOMIC UTILITY IN THE EVALUATION OF PATIENTS WITH SIGNS AND SYMPTOMS OF COGNITIVE IMPAIRMENT. W. Canestaro¹, R. Bateman², D. Holtzman², M. Monane³, J. Braunstein³(1. University of Washington School of Pharmacy - Seattle (United States), 2. Washington University School of Medicine - St Louis (United States), 3. C2N Diagnostics - St Louis (United States))

OC08- A PHASE 2B CLINICAL TRIAL OF NEFLAMAPIMOD IN DEMENTIA WITH LEWY BODIES DESIGNED TO CONFIRM THE EFFICACY RESULTS FROM PHASE 2A. N.D. Prins¹, A. Gardner², H.M. Chu³, K. Blackburn², J.E. Galvin⁴, J.J. Alam²(1. Brain Research Center - Amsterdam (Netherlands), 2. EIP Pharma Inc - Boston (United States), 3. Anoixis Corporation - Natick (United States), 4. University of Miami Miller School of Medicine - Boca Raton (United States))

OC09- ACCELERATED B-AMYLOID PLAQUE REDUCTION IN ALZHEIMER'S DISEASE COMBINING ADUCANUMAB INFUSION WITH FOCUSED ULTRASOUND BLOOD-BRAIN BARRIER OPENING. A.L.I.R. Rezai, P. D'haese, M. Haut, M. Ranjan, J. Carpenter, R. Mehta, K. Wilhelmsen, P. Wang, V. Finomore, S. Hodder (WVU Rockefeller Neuroscience Institute - Morgantown (United States))

OC10- ALLOPREGNANOLONE REGENERATIVE THERAPEUTIC FOR MILD ALZHEIMER'S DISEASE (REGEN-BRAIN©). R. Brinton¹, G. Hernandez¹, C. Lopez¹, L. Schneider²(1. University of Arizona - Tucson (United States), 2. University of Southern California - Los Angeles (United States))

OC11- PEPINEMAB, A SEMA4D BLOCKING ANTIBODY, IS A NOVEL POTENTIAL TREATMENT FOR NEURODEGENERATIVE DISEASE: CLINICAL PROOF OF CONCEPT IN PHASE 2 HD STUDY SUPPORTS CLINICAL DEVELOPMENT IN AN ONGOING PHASE 1/2 AD STUDY. T. Fisher¹, E. Evans¹, M. Boise¹, V. Mishra¹, C. Mallow¹, J. Leonard¹, E. Siemers², R. Turner³, W. Bond⁴, J. Huffaker⁴, and all the SIGNAL AD study investigators, M. Zauderer¹(1. Vaccinex, Inc. - Rochester (United States), 2. Siemers Integration LLC - Indianapolis (United States), 3. Re-Cognition Health - Fairfax (United States), 4. Neuropsychiatric Research Center of Southwest Florida - Fort Myers (United States))

OC12- ASTROCYTE REACTIVITY BIOMARKER FOR THE POPULATIONAL ENRICHMENT OF CLINICAL TRIALS IN PRECLINICAL ALZHEIMER'S DISEASE. B. Bellaver¹, G. Povala¹, P. C.l. Ferreira¹, J.P. Ferrari-Souzav, D. Teixeira Leffa¹, F. Z. Lussier¹, A. L. Benedet², N. J. Ashton², E. R. Zimmer³, H. Zetterberg², K. Blennow², A. Cohen¹, T. K. Karikari¹, P. Rosa-Neto⁴, T. A. Pascoal¹(1. University of Pittsburgh - Pittsburgh (United States), 2. University of Gothenburg - Gothenburg (United States), 3. Universidade Federal do Rio Grande do Sul - Porto Alegre (United States), 4. McGill University - Montreal (United States))

OC15- STRESS TESTING THE CL CONCEPT: EVALUATING CENTILOID STABILITY TO TRACER, EFFECTIVE IMAGE RESOLUTION AND QUANTIFICATION METHOD. M. Shekari^1,2,3, D. Vállez García⁴, L.E. Collij⁴, D. Altomare⁵, F. Heeman⁴, H. Pemberton^6,7, N. Roé Vellvé⁸, S. Bullich⁸, C. Buckley⁶, A. Stephens⁸, G. Farrar⁶, G. Frisoni⁵, W.E. Klunk⁹, F. Barkhof^4,7, J.D. Gispert^1,2,10(1. Barcelonaßeta Brain Research Center (BBRC), Pasqual Maragall Foundation - Barcelona (Spain), 2. IMIM (Hospital del Mar Medical Research Institute) - Barcelona (Spain), 3. Universitat Pompeu Fabra - Barcelona (Spain), 4. Amsterdam UMC, Vrije Universiteit Amsterdam - Amsterdam (Netherlands), 5. Memory Center, University Hospitals and University of Geneva - Geneva (Switzerland), 6. GE Healthcare Pharmaceutical Diagnostics, UK - Amersham (United Kingdom), 7. University College London - London (United Kingdom), 8. Life Molecular Imaging GmbH - Berlin (Germany), 9. University of Pittsburgh - Pittsburgh (United States), 10. Centro de Investigación Biomédica en Red Bioingeniería, Biomateriales y Nanomedicina, (CIBER-BBN) - Barcelona (Spain))

OC16- END-TO-END AUTOMATED SCORING OF SPEECH-BASED COGNITIVE ASSESSMENTS FOR ALZHEIMER'S DISEASE: A COMPARISON WITH MANUAL SCORING IN THE AMYPRED-US AND AMYPRED-UK STUDIES. J. Weston¹, U. Meepegama¹, C. Skirrow¹, M. Ropacki², E. Fristed²(1. Novoic - London (United Kingdom), 2. Oryzon - Temecula (United States))

OC17- CHARACTERIZATION OF THE SYNAPTIC BLOOD MARKER B-SYNUCLEIN IN DIFFERENT STAGES OF ALZHEIMERS DISEASE AND OTHER DEMENTIAS. P. Oeckl¹, G. Bellomo², L. Barba³, D. Alcolea⁴, A.L. Wojdala², J. Fortea⁴, A. Lleó⁴, L. Parnetti², O. Belbin⁴, M. Otto³(1. Ulm University Hospital, Department of Neurology and DZNE Ulm - Ulm (Germany), 2. Section of Neurology, Department of Medicine and Surgery, University of Perugia - Perugia (Italy), 3. Department of Neurology, Martin-Luther-University of Halle-Wittenberg - Halle (saale) (Germany), 4. Memory Unit, Department of Neurology, Institut d'Investigacions Biomèdiques Sant Pau - Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain - Barcelona (Spain))

OC18- REMOTE DETECTION AND CHARACTERIZATION OF COGNITIVE PERFORMANCE TRAJECTORIES IN MILD COGNITIVE IMPAIRMENT AND POPULATIONS AT-RISK FROM THE INTUITION BRAIN HEALTH STUDY. M. Butler¹, R. Brown¹, A. Becker¹, M. Hobbs¹, P. Saha-Chaudhuri¹, J. Penalver-Andres¹, D. Roggen¹, A. Scotland¹, Y. Zabar¹, R. Hughes¹, H. Lenyoun², M. Bianchi², A. Gabelle¹, S. Belachew¹, T. Intuition Scientific Study Committee¹(1. Biogen - Cambridge (United States), 2. Apple - Cupertino (United States))

OC19- BINDING PROFILES OF LECANEMAB AND DONANEMAB TO DIFFERENT AMYLOID-BETA SPECIES. L. Lannfelt^1,2, M. Johannesson¹, P. Nygren¹, A. Rachalski¹, E. Button¹, A.S. Svensson¹, E. Gkanatsiou¹, N. Fritz¹, O. Zachrisson¹, L. Söderberg¹, C. Möller¹(1. BioArctic AB - Stockholm (Sweden), 2. Department of Public Health/Geriatrics - Uppsala (Sweden))

OC20- ESTIMATING TIME-SAVING TREATMENT EFFECTS IN ALZHEIMER'S CLINICAL TRIALS: EXPLORING ALTERNATIVE APPROACHES. G. Wang¹, G. Cutter², L. Schneider³, W. Wang⁴, B. Mangal⁴, Y. Liao⁵, Y. Li¹, C. Xiong¹, J.L.L.I.B. Llibre-Guerra¹, E.R.I.C.M. Mcdade¹, R. Bateman¹(1. Washington University School of Medicine, St. Louis, MO - St Louis (United States), 2. University of Alabama at Birmingham - Birmingham (United States), 3. Keck School of Medicine, University of Southern California - Los Angeles (United States), 4. Alector, Inc - San Francisco (United States), 5. Asher Biotherapeutics - San Francisco (United States))

OC21- THE POTENTIAL FOR TIME SAVINGS IN EARLY ALZHEIMER CLINICAL TRIALS. L. Schneider¹, G. Wang², R. Kennedy³, G. Cutter³(1. Keck School of Medicine of USC - Los Angeles (United States), 2. Washington University - Saint Louis (United States), 3. University of Alabama, Birmingham - Birmingham (United States))

OC22- PRECISION MEDICINE ANALYSIS OF HETEROGENEITY IN INDIVIDUAL-LEVEL TREATMENT RESPONSE TO BETA-AMYLOID REMOVAL IN EARLY ALZHEIMER'S DISEASE. M. Pang¹, A. Gabelle¹, P. Saha-Chaudhuri¹, W. Huijbers¹, A. Gafson¹, P. Matthews², L. Tian³, I. Rubino¹, R. Hughes¹, C. De Moor¹, S. Belachew¹, C. Shen¹(1. Biogen - Cambridge (United States), 2. Imperial College London - London (United Kingdom), 3. Stanford University School of Medicine - Stanford (United States))

OC23- EFFECTS OF AN 18-MONTH MULTIMODAL INTERVENTION ON COGNITIVE FUNCTION (J-MINT PRIME TAMBA): A RANDOMIZED CONTROLLED TRIAL. Y. Oki¹, T. Osaki², R. Kumagai³, S. Murata⁴, H. Encho³, H. Yasuda¹, R. Ono⁵, H. Kowa³(1. Department of Public Health, Kobe University Graduate School of Health Sciences - Kobe (Japan), 2. Department of Occupational Therapy, Faculty of Rehabilitation, Kobe Gakuin University - Kobe (Japan), 3. Department of Rehabilitation Science, Kobe University Graduate School of Health Sciences - Kobe (Japan), 4. Department of Preventive Medicine and Epidemiology, National Cerebral and Cardiovascular Center Research Institute - Suita (Japan), 5. Department of Physical Activity Research, National Institute of Health and Nutrition, National Institutes of Biomedical Innovation, Health and Nutrition - Ibaraki (Japan))

OC24- ALZHEIMER'S DISEASE IN DOWN SYNDROME: NATURAL HISTORY, BIOMARKERS AND CLINICAL TRIALS. M. Rafii¹, J. Fortea², B. Ances³(1. University of Southern California - San Diego (United States), 2. Hospital san Pau - Barcelona (Spain), 3. Washington University - Saint Louis (United States))

OC25- RISK OF INCIDENT COGNITIVE IMPAIRMENT USING STAGES OF OBJECTIVE MEMORY IMPAIRMENT (SOMI) AND NEUROIMAGING. K. Petersen¹, A. Ezzati², B. Nallapu¹, R. Lipton¹, R. Sperling³, K. Papp³, D. Rentz³, E. Grober¹(1. Albert Einstein College of Medicine - Bronx (United States), 2. University of California, Irvine - Irvine (United States), 3. Harvard Medical School - Boston (United States))

OC26- QUANTITATIVE AMYLOID-PET IN REAL-WORLD PRACTICE: LESSONS FROM THE IMAGING DEMENTIA—EVIDENCE FOR AMYLOID SCANNING (IDEAS) STUDY. R. La Joie¹, E. Zeltzer¹, N. Mundada¹, G. Blazhenets¹, J. Mejia Perez¹, D. Schonhaut¹, L. Iaccarino², M. Carrillo³, L. Hanna⁴, C. Gatsonis⁴, A. March⁵, B. Siegel⁶, B. Hillner⁷, R. Whitmer⁸, G. Rabinovici¹(1. University of California, San Francisco - San Francisco, Ca (United States), 2. Avid Radiopharmaceuticals - Philadelphia, Pa (United States), 3. Alzheimer's Association - Chicago, Il (United States), 4. Brown university - Providence, Ri (United States), 5. American College of Radiology - Philadelphia, Pa (United States), 6. Washington University School of Medicine in St. Louis - St Louis, Mo (United States), 7. Virginia Commonwealth University - Richmond, Va (United States), 8. University of California, Davis - Davis, Ca (United States))

OC27- MEASURING MEANINGFUL BENEFIT OF DISEASE MODIFYING TREATMENT ON HEALTH-RELATED RESOURCE USE. C. Zhu¹, M. Sano¹(1. Icahn School of Medicine at Mount Sinai - New York (United States))

OC28- ESTABLISHING THE VALIDITY OF A NOVEL ELECTRONIC CLINICAL DEMENTIA RATING (ECDR). R. Nosheny¹, D. Yen², T. Howell¹, M. Camacho³, K. Moulder², M. Ashford³, R. Petersen⁴, N. Stricker⁴, E. Roberson⁵, D. Marson⁵, W. Kukull⁶, S. Mackin¹, M. Weiner¹, J. Morris², Y. Li²(1. UCSF - San Francisco (United States), 2. Washington University - St. Louis (United States), 3. Northern California Institute for Research and Edcuation - San Francisco (United States), 4. Mayo Clinic - Rochester (United States), 5. University of Alabama at Birmingham - Birmingham (United States), 6. University of Washington - Seattle (United States))

OC29- AI-BASED ENRICHMENT TOOLS SUBSTANTIALLY INCREASE THE EFFICIENCY OF AD CLINICAL TRIALS. V. Devanarayan¹, Y. Ye¹, H. Hampel¹, L. Kramer¹, M. Irizarry¹, S. Dhadda¹(1. Eisai Inc. - Nutley (United States))

OC30- TIMING OF BIOMARKER CHANGES IN SPORADIC ALZHEIMER DISEASE IN ESTIMATED YEARS FROM SYMPTOM ONSET. Y. Li¹, D. Yen¹, R. Hendrix¹, B. Gordon¹, S. Dlamini¹, N. Barthelemy¹, A. Aschenbrenner¹, R. Henson¹, E. Mcdade¹, D. Holtzman¹, T. Benzinger¹, J. Morris¹, R. Bateman¹, S. Schindler¹(1. Washington University in St. Louis - St. Louis (United States))

OC31- RG6289, A NEW y-SECRETASE MODULATOR FOR THE TREATMENT OF ALZHEIMER'S DISEASE: RESULTS FROM A PHASE I HEALTHY VOLUNTEER STUDY. S. Sturm¹, A. Portron¹, A. Vogt², A. Poirier¹, T. Yang³, A. Mohamed Abdi¹, G. Kollmorgen⁴, C. Simmons⁵, K. Mahil⁶, L. Lindemann², K.H. Baumann², T. Mueggler², T. Vardar⁷, R. Tortelli², I. Gerlach²(1. Pharmaceutical Sciences, Roche Pharma Research and Early Development, F. Hoffmann-La Roche Ltd - Basel (Switzerland), 2. Neuroscience and Rare Diseases, Roche Pharma Early Research and Development, F. Hoffmann-La Roche Ltd - Basel (Switzerland), 3. Product Development Safety Risk Management (PDS), F. Hoffmann-La Roche Ltd - Beijing (China), 4. Roche Diagnostics GmbH - Penzberg (Germany), 5. Product Development Data Sciences, F. Hoffmann-La Roche Ltd - Mississauga (Canada), 6. Roche Innovation Center Welwyn, Roche Pharma Research and Early Development, Roche Products Limited - Welwyn (United Kingdom), 7. Product Development Safety Risk Management (PDS), F. Hoffmann-La Roche Ltd - Basel (Switzerland))

OC32- A PHASE 1A SINGLE ASCENDING DOSE STUDY OF THE SAFETY, TOLERABILITY, AND BRAIN RECEPTOR OCCUPANCY OF BMS-984923 IN HEALTHY OLDER ADULTS. A.P. Mecca¹, E. Salardini¹, J.D. Gallezot¹, R.S. O'dell¹, J. Young¹, E. Cooper¹, M.G. Donahue¹, J.L. Waszak¹, J.L. May¹, J. Spurrier¹, T.R. Siegert², R.E. Carson¹, S.M. Strittmatter^1,2, C.H. Van Dyck¹(1. Yale School of Medicine - New Haven (United States), 2. Allyx Therapeutics, Inc. - New Haven (United States))

OC33- A PHASE 1 STUDY DEMONSTRATING SAFETY, CNS TARGET ENGAGEMENT AND PBMC PHARMACODYNAMIC RESPONSE TO ASN51, A NOVEL AND ORALLY ADMINISTERED O-GLCNACASE INHIBITOR. R. Schubert¹, B. Permanne¹, R. Pokorny¹, P. Fang¹, V. Teachout¹, M. Nény¹, S. Ousson¹, R. Ahmed¹, M. Schneider¹, A. Quattropani¹, D. Beher¹(1. Asceneuron - Lausanne (Switzerland))

OC34- E2511, A NOVEL TRKA MODULATOR, ENGAGES ITS CNS CHOLINERGIC TARGET IN A PHASE 1 CLINICAL STUDY. S. Saxena¹, Y. Ye¹, K. Sasaki¹, T. Kamakura¹, G. Ringheim¹, L. Giorgi¹, N. Penner¹, K. Horie¹, V. Devanarayan¹, P. Sachdev¹(1. Eisai Inc. - Nutley (United States))

OC35- MODE OF ACTION, CLINICAL PHASE IB DATA IN PATIENTS, AND THE PHASE II DESIGN OF THE ORALLY AVAILABLE ANTI-PRIONIC COMPOUND PRI-002 THAT DISASSEMBLES AB OLIGOMERS INTO AB MONOMERS. D. Willbold¹, N.C. Cosma², J. Kutzsche¹, D. Jörgens³, G. Tischler³, O. Peters²(1. FZ Jölich - Jölich (Germany), 2. Charité - Berlin (Germany), 3. Prinnovation - Leipzig (Germany))

Late Breaking Communications

LB01- BASELINE LEVELS AND LONGITUDINAL CHANGES IN PLASMA AB42/40AMONG SELF-IDENTIFIED BLACK AND WHITE INDIVIDUALS. C. Xiong¹, J. Luo¹, D. Wolk², L. Shaw², E. Roberson³, R. Henson¹, T. Benzinger¹, Q. Bui¹, F. Agboola¹, E. Grant¹, E. Gremminger¹, K. Moulderv, D. Holtzman¹, J. Morris¹, S. Schindler¹(1. Washington University - St. Louis (United States), 2. University of Pennsylvania - Philadelphia (United States), 3. University of Alabama - Birmingham (United States))

LB02- PLASMA MTBR-TAU243 IS A SPECIFIC BIOMARKER OF TAU TANGLE PATHOLOGY IN ALZHEIMER'S DISEASE. K. Horie^1,2,3, R. Koppisetti^1,2, S. Janelidze⁴, E. Stomrud^4,5, N. Barthélemy^1,2, C. Sato^1,2, T. Benzinger⁶, D. Holtzman², J. Morris², N. Mattsson-Carlgren^4,5, S. Palmqvist^4,5, S. Schindler², O. Hansson^4,5, R. Bateman^1,2(1. Tracy Family SILQ Center, Washington University School of Medicine - St. Louis (United States), 2. Department of Neurology, Washington University School of Medicine - St. Louis (United States), 3. Eisai Inc - Nutley (United States), 4. Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University - Lund (Sweden), 5. Memory Clinic, Skåne University Hospital - Malmö (Sweden), 6. Department of Radiology, Washington University School of Medicine - St. Louis (United States))

LB03- TOPLINE RESULTS FROM THE PHASE 2 PIONEER TRIAL OF ORAL T3D-959 FOR THE TREATMENT OF PATIENTS DIAGNOSED WITH MILD-TO-MODERATE ALZHEIMER'S DISEASE. J. Stanek¹, S. Chamberlain¹, C. Coutlee¹, W. Strittmatter¹, C. Lineberry¹, B. Swearingen¹, J. Didsbury¹(1. T3D Therapeutics, Inc. - Research Triangle Park (United States))

LB04- SAFETY, IMMUNOGENICITY, CLINICAL EFFICACY AND BIOMARKERS OF ABVAC40, AN ACTIVE VACCINE ANTI-AB40 IN PATIENTS WITH AMNESTIC MILD COGNITIVE IMPAIRMENT OR VERY MILD ALZHEIMER'S DISEASE: FINAL RESULTS OF A PHASE 2 RANDOMIZED STUDY. J. Terencio^1,2, M. Pascual-Lucas³, A.M. Lacosta³, M. Montañés³, J. Canudas³, J.A. Allué³, L. Sarasa³, N. Fandos³, J. Romero³, E. Molina³, M. Sarasa³, M. Boada⁴(1. Grifols - Barcelona (Spain), 2. Araclon Biotech-Grifols - Zaragoza (Spain), 3. Araclon-Biotech - Zaragoza (Spain), 4. Ace Alzheimer Center Barcelona - Universitat Internacional de Catalunya - Barcelona (Spain))

LB05- TAU VACCINE AADVAC1 DEMONSTRATES CLINICAL AND BIOMARKER EFFICACY ON PATIENTS WITH PLASMA P-TAU217 DEFINED ALZHEIMER'S DISEASE IN PHASE II CLINICAL TRIAL: POST HOC ANALYSIS. B. Kovacech¹, N. Cullen², P. Novak¹, J. Hanes¹, E. Kontsekova¹, M. Fresser³, J. Vanbrabant⁴, H. Feldman⁵, B. Winblad⁶, E. Stoops⁴, E. Vanmechelen⁴, N. Zilka¹(1. Axon Neuroscience R&D Services - Bratislava (Slovakia), 2. Department of Clinical Sciences, Lund University - Lund (Sweden), 3. Axon Neuroscience SE - Larnaca (Cyprus), 4. ADx NeuroSciences NV, Technologiepark 94 - Bio Incubator - Gent (Belgium), 5. Department of Neurosciences, University of California San Diego - La Jolla (United States), 6. Karolinska Institutet, Dept NVS, Center for Alzheimer Research, Division of Neurogeriatrics - Solna (Sweden))

LB06- POOLED ENGAGE/EMERGE INTEGRATED PLACEBO-CONTROLLED PERIOD AND LONG-TERM EXTENSION (LTE) TOPLINE RESULTS: SLOWER CLINICAL PROGRESSION AT WEEK 134 IN ADUCANUMAB-TREATED PATIENTS THAT BECAME AMYLOID PET NEGATIVE AT WEEK 78. J. O'Gorman¹, J. Murphy¹, P. Montenigro¹, S. Showell¹, G. Dent¹, C. Rubel¹, R.M. Hutchison¹, T. Chen¹, K. Kandadi Muralidharan¹, K. Dawson¹(1. Biogen - Cambridge (United States))

LB07- PRECIVITYAD2 BLOOD TEST: AN ANALYTICALLY AND CLINICALLY VALIDATED TEST COMBINING P-TAU217/NP-TAU217 AND AB42/40 RATIOS TO IDENTIFY BRAIN AMYLOID. K. Kirmess¹, M. Meyer¹, T. Wente-Roth¹, F. Irwin¹, M. Holubasch¹, S. Eastwood¹, V. Venkatesh¹, M. Irizarry², D. Verbel², P. Sachdev², S. Ito², K. Yarasheski¹, J. Braunstein¹, P. Verghese¹, T. West¹(1. C2N Diagnostics - St. Louis (United States), 2. Eisai Inc. - Nutley (United States))

LB08- EFFICACY OF DONANEMAB BY APOE4 CARRIER STATUS IN TRAILBLAZER-ALZ 2, A PHASE 3 RANDOMIZED CLINICAL TRIAL IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE. C.D. Evans¹, J.A. Zimmer¹, A.M. Wessels¹, M. Lu¹, J. Sparks¹, M. Mintun¹, D.A. Brooks¹, J.R. Sims¹(1. Eli Lilly and Company - Indianapolis (United States)

LB09- EXPLORATORY CLINICAL OUTCOMES FROM BIIB080 (MAPT ASO) PHASE 1B MULTIPLE ASCENDING DOSE AND LONG-TERM EXTENSION STUDY IN MILD ALZHEIMER'S DISEASE. N. Ziogas¹, S. Wu¹, Y. Li¹, L. Lin¹, A. Edwards¹, J. Collins¹, I. Tien¹, C. Mummery², R. Lane³, C. Junge³, J. Beaver¹, Y. Tian¹, J. Landen¹, D. Gallagher¹, M. Shulman¹(1. Biogen - Cambridge (United States), 2. Dementia Research Centre, National Hospital for Neurology and Neurosurgery, University College London - London (United Kingdom), 3. Ionis Pharmaceuticals - Carlsbad (United States))

LB10- PHASE 1 SAFETY, TOLERABILITY, AND PHARMACOLOGICAL RESULTS OF ALN-APP, THE FIRST INVESTIGATIONAL RNA INTERFERENCE THERAPEUTIC IN DEVELOPMENT FOR EARLY-ONSET ALZHEIMER'S DISEASE. C. Mummery¹, S. Ducharme², J. Brosch³, E. Vijverberg⁴, L. Apostolova³, A. Sostelly⁵, S. Goteti⁵, N. Makarova⁵, A. Avbersek⁶, W. Guo⁵, B. Bostwick⁵, S. Cohen⁷(1. University College London - London (United Kingdom), 2. Douglas Mental Health University Institute, Department of Psychiatry and Montreal Neurological Institute, Department of Neurology & Neurosurgery, McGill University - Montreal, Quebec (Canada), 3. Indiana University School of Medicine - Indianapolis, Indiana (United States), 4. Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Amsterdam UMC - Amsterdam (Netherlands), 5. Alnylam Pharmaceuticals - Cambridge, Massachusetts (United States), 6. Regeneron Pharmaceuticals, Inc. - Tarrytown, New York (United States), 7. Toronto Memory Program - Toronto, Ontario (Canada))

LB11- RAPID AMYLOID CLEARANCE AND EFFICACY: RESULTS FROM TRAILBLAZER-ALZ 2, A PHASE 3 STUDY OF DONANEMAB FOR TREATMENT OF EARLY ALZHEIMER'S DISEASE. S. Shcherbinin¹, M. Lu¹, J. Wang¹, H. Wang¹, P. Hauck¹, I. Gueorguieva¹, D. Brooks¹, J. Sims¹, M. Mintun¹, E. Collins¹(1. Eli Lilly and Company - Indianapolis (United States))

LB12- REDUCED CAREGIVER DISTRESS ASSOCIATED WITH NEUROPSYCHIATRIC SYMPTOMS IN EMERGE, A PHASE 3, DOUBLE-BLIND CLINICAL TRIAL OF ADUCANUMAB IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE. J. Cummings¹, S. Cohen², J. Murphy³, P. He⁴, C. De Moor⁵, F. Forrestal³, J. Harrison^6,7, J. Jaeger^8,9, C.J. Mummery¹⁰, A.P. Porsteinsson¹¹, M. Potashman¹², Y. Tian³, L. Yang¹³, J. O'gorman³, S. Budd Haeberlein¹⁴(1. Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, UNLV - Las Vegas (United States), 2. Toronto Memory Program - Toronto (Canada), 3. Biogen Inc. - Cambridge (United States), 4. Takeda Pharmaceutical Company Limited - Boston (United States), 5. Certara - Princeton (United States), 6. Scottish Brain Sciences - Edinburgh (United Kingdom), 7. Alzheimercentrum of the Amsterdam UMC - Amsterdam (Netherlands), 8. CognitionMetrics, LLC - Stamford (United States), 9. Albert Einstein College of Medicine - New York (United States), 10. Dementia Research Centre, Queen Square Institute of Neurology, University College London - London (United Kingdom), 11. University of Rochester School of Medicine and Dentistry - Rochester (United States), 12. Biohaven Pharmaceuticals Inc - New Haven (United States), 13. Alnylam Pharmaceuticals - Cambridge (United States), 14. Enigma Biomedical USA - Nashville (United States))

LB13- TIME SAVINGS ESTIMATES FOR DONANEMAB TRAILBLAZER-ALZ PHASE 2 & PHASE 3 STUDIES. S.P. Dickson¹, S.B. Hendrix¹, L.L. Raket², S. Chatterjee², J. Christensen¹, B. Haaland¹, J. Sparks², J.R. Sims², D.A. Brooks², M.A. Mintun²(1. Pentara Corporation - Salt Lake City (United States), 2. Eli Lilly and Company - Indianapolis (United States))

LB14- EVIDENCE THAT LUMIPULSE G PTAU217 PLASMA MEASUREMENTS HAVE THE ABILITY TO QUANTITATIVELY ASSESS TAU STAGE AND BURDEN. A. Bannon¹, E. Stage¹, M. Vandijck², F. Desimone², J. Lawson³, L. Ward⁴, V. Doré⁵, J. Doecke⁶, C. Fowler⁴, J. Mejan-Fripp⁶, C. Rowe⁴(1. AbbVie Inc - North Chicago (United States), 2. Fujirebio - Antwerp (Belgium), 3. Fujirebio - Malvern (United States), 4. The Florey Institute of Neuroscience and Mental Health - Melbourne (Australia), 5. CSIRO - Melbourne (Australia), 6. CSIRO - Brisbane (Australia))

LB15- AN EXPLORATION OF AMYLOID REMOVAL MEASURES IN RELATION TO CLINICAL BENEFIT: A REVIEW AND META-REGRESSION OF ANTI-AMYLOID TRIALS IN AD. M.A. Scelsi¹, J. Jackson¹, M. Tonietto², G. Klein², C. Lane¹, J. Smith¹, R. Doody², P. Delmar²(1. Roche Products Ltd - Welwyn Garden City (United Kingdom), 2. F. Hoffman-La Roche AG - Basel (Switzerland))

LB16- PROGRESSION ANALYSIS ON COGNITIVE, FUNCTIONAL, AND BEHAVIORAL ENDPOINTS IN EMERGE, A PHASE 3, DOUBLE-BLIND CLINICAL TRIAL OF ADUCANUMAB IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE. S. Cohen¹, J. Cummings², J. Murphy³, P. He⁴, M. Levitchi Benea⁵, F. Forrestal³, J. Harrison^6,7, J. Jaeger^8,9, C.J. Mummery¹⁰, A.P. Porsteinsson¹¹, M. Potashman¹², L. Yang¹³, S. Wu³, Y. Tian³, S. Budd Haeberlein¹⁴(1. Toronto Memory Program - Toronto (Canada), 2. University of Las Vegas - Las Vegas (United States), 3. Biogen Inc. - Cambridge (United States), 4. Takeda Pharmaceutical Company Limited - Boston (United States), 5. Fulcrum Therapeutics - Cambridge (United States), 6. Scottish Brain Sciences - Edinburgh (United Kingdom), 7. Alzheimercentrum of the AUmC - Amsterdam (Netherlands), 8. CognitionMetrics, LLC - Stamford (United States), 9. Albert Einstein College of Medicine - New York (United States), 10. Dementia Research Centre, Queen Square Institute of Neurology, University College London - London (United Kingdom), 11. University of Rochester School of Medicine and Dentistry - Rochester (United States), 12. Biohaven Pharmaceuticals, Inc. - New Haven (United States), 13. Alnylam Pharmaceuticals - Cambridge (United States), 14. Enigma Biomedical USA - Nashville (United States))

LB17- TOPLINE RESULTS OF A PHASE II TRIAL OF EDONERPIC MALEATE IN PATIENTS WITH EARLY STAGE BIOMARKER-PROVEN ALZHEIMER'S DISEASE. N. Prins¹, C. Teunissen², P. Van Bokhoven³, S. Sikkes⁴, W. De Haan⁴, T. Okuda⁵, P. Scheltens⁶(1. Brain Research Center - Amsterdam (Netherlands), 2. Neurochemistry Laboratory, Department of Neurochemistry, Amsterdam UMC - Amsterdam (Netherlands), 3. IXA-Neuroscience, Amsterdam Neuroscience, Amsterdam UMC location Vrije Universiteit - Amsterdam (Netherlands), 4. Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location Vumc - Amsterdam (Netherlands), 5. FUJIFILM Toyama Chemical Co., Ltd. - Tokyo (Japan), 6. Amsterdam UMC - Amsterdam (Netherlands))

LB18- CT1812 START STUDY DESIGN: ANTI-AB MONOCLONAL ANTIBODIES AS BACKGROUND THERAPY. C. Van Dyck¹, R. Raman², M. Donohue², R. Rissman², M. Rafii¹, M. Hamby³, M. Grundman³, A. Caggiano³, P. Aisen²(1. Yale School of Medicine - New Haven (United States), 2. Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego - San Diego (United States), 3. Cognition Therapeutics Inc. - Pittsburgh (United States))

LB19- PHARMACOKINETIC-PHARMACODYNAMIC (PK-PD) RELATIONSHIP BETWEEN ADUCANUMAB EXPOSURE AND AMYLOID PET OVER LONG-TERM TREATMENT PERIOD INCLUDING DOSING GAP IN THE EMBARK PHASE 3B STUDY. J. Burton¹, K. Ken², K. Kandadi Muralidharan¹, R.M. Hutchison¹, P. Montenigro¹, I. Nestorov¹(1. Biogen - Cambridge (United States), 2. Kowalski PMetrics Consulting LLC - Naples (United States))

LB20- A MASS SPECTROMETRIC PANEL OF PHOSPHORYLATED AND NON-PHOSPHORYLATED PLASMA TAU SPECIES REVEALS DIFFERENCES IN THE ASSOCIATIONS WITH EARLY AND INTERMEDIATE TAU PET IN SPORADIC ALZHEIMER'S DISEASE. Laia Montoliu-Gaya¹, Gemma Salvado², Nicholas J Ashton¹, Shorena Janelidze², Johanna Nilsson³, Niklas Mattsson-Carlgren², Sophia Weiner⁴, Sebastian Palmqvist², Juan Lantero-Rodriguez³, Gunnar Brinkmalm⁴, Erik Stomrud², Henrik Zetterberg³, Johan Gobom³, Kaj Blennow³, Oskar Hansson²(1. University of Gothenburg - Gothenburg (Sweden), 2. Lund University - Lund (Sweden), 3. University of Gothenburg - Gothenburg (Sweden) - Gothenburg (Sweden), 4. University of Gothenburg - Gothenburg (Sweden) - Gothenburg (Sweden) - Gothenburg (Sweden))

LB21- EVALUATING THE EFFICACY OF AR1001 ON PLASMA PTAU 181 LEVELS AND ADAS-COG 13 IN MILD TO MODERATE ALZHEIMER'S DISEASE: RESULTS FROM THE PHASE 2 TRIAL. B.S. Ye¹, D. Greeley², F. Kim², J.J. Choung²(1. Department of Neurology, Yonsei University College of Medicine - Seoul (Korea, Republic of), 2. AriBio Co., Ltd. - Seongnam (Korea, Republic of))

LB22- ADUCANUMAB PHASE 3B EMBARK STUDY INTERIM ANALYSIS: TOPLINE SAFETY RESULTS. G.G. Curiale¹, P. Montenigro¹, K. Umans¹, T. Sun¹, J. O'gorman¹, K. Smirnakis¹(1. Biogen - Cambridge (United States))

LB23- RESULTS OF A PHASE 2 RANDOMIZED WITHDRAWAL STUDY OF SIMUFILAM IN MILD-TO-MODERATE ALZHEIMER'S DISEASE. I. Cohen¹, S. Malhotra¹, P. Patel², S. Hendrix³, C. Mallinckrodt³, B. Murray⁴, L. Jones⁴, A. Hernandez⁴, E.C.R.O.W. Crow⁴, M. Snyder⁴, L. Burns⁴, J. Kupiec⁴, N. Friedmann⁴(1. Toronto Memory Program - Toronto (Canada), 2. Brain Matters Research - Delray Beach (United States), 3. Pentara Corporation - Millcreek (United States), 4. Cassava Sciences, Inc. - Austin (United States))

LB24- PLASMA P-TAU212 IDENTIFIES COGNITIVELY UNIMPAIRED INDIVIDUALS WITH EMERGING AMYLOID-BETA PATHOLOGY. P. Kac¹, A. González-Escalante^2,3,4, M. Milà-Alomà^2,5, N. Ashton^1,6,7,8, M. Shekari^2,3,4,5, P. Ortiz-Romero^2,3, H. Zetterberg^1,6,9,10, J.D. Gispert^2,3,5,11, K. Blennow^1,12, M. Suárez-Calvet^2,3,11,13, T. Karikari^1,14(1. Department of Psychiatry and Neurochemistry,Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg - Mölndal (Sweden), 2. Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation - Barcelona (Spain), 3. Hospital del Mar Research Institute - Barcelona (Spain), 4. Universitat Pompeu Fabra - Barcelona (Spain), 5. Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES) - Madrid (Spain), 6. Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King's College London - London (United Kingdom), 7. NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation - London (United Kingdom), 8. Centre for Age-Related Medicine, Stavanger University Hospital - Stavanger (Norway), 9. Hong Kong Center for Neurodegenerative Diseases, HKCeND - Hong Kong (China), 10. School of Medicine and Public Health, University of Wisconsin-Madison - Madison (United States), 11. Centro de Investigación Biomédica en Red Bioingeniería, Biomateriales y Nanomedicina - Madrid (Spain), 12. Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital - Mölndal (Sweden), 13. Servei de Neurologia, Hospital del Mar - Barcelona (Spain), 14. Department of Psychiatry, School of Medicine, University of Pittsburgh - Pittsburgh (United States))

LB25- ELEVATED AMYLOID AND TAU ARE NOT ASSOCIATED WITH COGNITION IN A DIVERSE CLINICAL TRIAL COHORT. S. Landau¹, T. Harrison¹, T. Ward¹, P. Vemuri², S. Lockhart³, R. Koeppe⁴, D. Harvey⁵, L. Lovato³, A. Toga⁶, S. Tomaszewski Farias⁵, K. Papp⁷, H. Snyder⁸, C. Decarli⁵, W. Jagust¹, L. Baker³(1. UC Berkeley - Berkeley (United States), 2. Mayo Clinic - Rochester (United States), 3. Wake Forest School of Medicine - Winston-Salem (United States), 4. University of Michigan - Ann Arbor (United States), 5. UC Davis - Davis (United States), 6. University of Southern California - Los Angeles (United States), 7. Harvard University - Boston (United States), 8. Alzheimer's Association - Chicago (United States))

LB26- FEASIBILITY OF REMOTE BLOOD COLLECTION AND PLASMA BIOMARKER ANALYSES TO ASSESS ELIGIBILITY FOR ALZHEIMER'S DISEASE PRECLINICAL CLINICAL TRIALS - THE ALZMATCH STUDY. R. Raman¹, S. Walter¹, G. Jimenez-Maggiora¹, R. Rissman¹, A. Atri², D. Goldman³, J. Grill⁴, G.A. Marshall⁵, G. Jicha⁶, M. Racke⁷, R. Turner⁸, C. Van Dyck⁹, V. Venkatesh¹⁰, R. Sperling⁵, P. Aisen¹(1. Alzheimer's Therapeutic Research Institute, University of Southern California - San Diego (United States), 2. Banner Sun Health Research Institute and Banner Alzheimer's Institute, Banner Health, Brigham And Women's Hospital - Sun City And Phoenix, Boston (United States), 3. Leonard D. Schaeffer Center for Health Policy and Economics, University of Southern California - Los Angeles (United States), 4. Institute for Memory Impairments and Neurological Disorders, University of California Irvine - Irvine (United States), 5. Massachusetts General Hospital, Harvard Medical School - Boston (United States), 6. University of Kentucky - Lexington (United States), 7. Quest Diagnostics - Secaucus (United States), 8. Georgetown University - Washington Dc (United States), 9. Yale College of Medicine - New Haven (United States), 10. C2N Diagnostics - St. Louis (United States))

LB27- TWELVE-MONTH RESULTS IN FTD-C9ORF72 PARTICIPANTS FROM INFRONT-2: A PHASE 2 STUDY OF LATOZINEMAB (AL001) IN FTD. L. Carter¹, P. Ljubenkov², H. Seelaar³, O. Kahn¹, L. Long¹, G. Chao¹, J. Okoronkwo¹, M. Smithey¹, J. Huang¹, W. Wangv, G. Romano¹, A. Ludolph⁴(1. Alector - South San Francisco (United States), 2. University of California San Francisco - San Francisco (United States), 3. Erasmus University Medical Center - Rotterdam (Netherlands), 4. University of Ulm and DZNE - Ulm (Germany))

LB28- DEVELOPMENT OF ORALLY AVAILABLE, BRAIN PENETRANT COMPOUND REDUCING TAU PATHOLOGY. B. Wolozin¹, P. Ash¹, A. Berson¹, C. Murphy¹, N. Fredette¹, B. Moore¹, J. Vacca¹, R. Schaub¹, G. Larsen¹(1. Aquinnah Pharmaceuticals Inc. - Cambridge (United States))

Esportazione

Vol 10 - N° S1

P. 4-55 - Novembre 2023 Ritorno al numero

Articolo precedente

Are We There Yet (and How Do We Get There…)?
R.A. Sperling

| Articolo seguente

16^th Clinical Trials on Alzheimer's Disease (CTAD) Boston, MA (USA) October 24–27, 2023: Posters

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.

connettersi o creare un account

16^th Clinical Trials on Alzheimer's Disease (CTAD) Boston, MA (USA) October 24–27, 2023: Symposia - 21/11/24

Mappa

Citazioni Export

File

Contenuto

Il mio account

Aide & support

Dichiarazione CNIL